# CRISPR Therapeutics

first CRISPR medicine in history, FDA approved Dec 2023 for SCD and Jan 2024 for TDT; ~1,000 US patients ≥12 yr eligible; paediatric sNDA under review 2026.

Source: https://en.bioecon.ru/companies/crispr-therapeutics/
Updated: 2026-06-24

- Country: Switzerland
- Ticker: CRSP

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $1,975.8 million. It has a history of recurring losses and will require additional capital. | https://crisprtx.gcs-web.com/static-files/758a3569-9792-4af2-a773-f5e71afea36a, https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/R12.htm |
| Production site | Wholly-owned, GMP manufacturing facility located in Framingham, Massachusetts. | https://crisprtx.com/who-we-are, https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-14, https://crisprtx.gcs-web.com/static-files/758a3569-9792-4af2-a773-f5e71afea36a, https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7, https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/R12.htm |
| Capacity | Provides end-to-end production capabilities for its cell therapy portfolio, supporting both clinical and commercial supply. | https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-14, https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7 |
| Regulatory approval | FDA approved CASGEVY for SCD and TDT in December 2023 (12+ years) and in 2026 for children 2 years and older. | https://ir.crisprtx.com/static-files/156e1fc1-277c-4ac7-a514-e90aa850a294, https://last10k.com/sec-filings/crsp/0001193125-26-330672.htm, https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease |
| Headcount | Estimates range from approximately 304 to 393 employees as of mid-2026. [medium confidence] | https://altindex.com/ticker/crsp/employees-linkedin, https://profit.com/ticker/CRSP/profile |
| Revenue | Reported $76 million in revenue for Q2 2026 and $116 million for full year 2025. | https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-14, https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7, https://last10k.com/sec-filings/crsp/0001193125-26-330672.htm |

Independent sources: altindex.com, crisprtx.com, crisprtx.gcs-web.com, fda.gov, ir.crisprtx.com, last10k.com, pmc.ncbi.nlm.nih.gov, profit.com, sec.gov

## Technologies

- [Genome editing](https://en.bioecon.ru/technology/genome-editing/)
- [Personalized & regenerative medicine](https://en.bioecon.ru/technology/personalized-regenerative-medicine/)